ABBV vs REPL
AbbVie Inc (ABBV) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
REPL does not have a complete income-statement cache yet.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. REPL currently screens at market cap $825.7M.
Not investment advice. Open the ABBV and REPL stock pages for the full models.
Not investment advice.